Maher Albitar

Maher Albitar discloses dealings in Neogenomics Inc to SEC (Form 4). Over a trading history stretching from 28 March 2014 to 23 September 2016, the count stands at 11 filings.

In open-market terms, that means 1 purchase worth €37k on one side and 5 sales worth €3.9M on the other. Sales outweigh purchases by €3.9M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 1 share grant and 4 option exercises. So far in 2016, the count stands at no purchases and 5 sales.

On 27 September 2016 came the latest disclosure, an open-market sale for €21k in Neogenomics Inc. The clock since the last published purchase (31 March 2014) now reads 4,606 days. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.